AstraZeneca - AZN Share Forecast, Price & News

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Down 0.0 %

AZN Stock opened at £108.40 ($130.98) on Wednesday. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 87.31. The firm has a 50-day moving average of £106.24 and a two-hundred day moving average of £100.17. AstraZeneca has a 12 month low of GBX 8,029 ($97.02) and a 12 month high of £112.90 ($136.41). The company has a market cap of £167.96 billion and a price-to-earnings ratio of -184.39.

AstraZeneca Cuts Dividend

The business also recently announced a dividend, which will be paid on Monday, September 12th. Shareholders of record on Thursday, August 11th will be paid a GBX 76.40 ($0.92) dividend. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend is Thursday, August 11th. AstraZeneca's dividend payout ratio (DPR) is presently -4.82%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays upped their price target on AstraZeneca from £120 ($145.00) to £125 ($151.04) and gave the stock an "overweight" rating in a report on Thursday, August 4th. Jefferies Financial Group set a GBX 9,800 ($118.41) target price on AstraZeneca in a research report on Thursday, July 7th. Credit Suisse Group set a £110 ($132.91) price target on shares of AstraZeneca in a report on Monday, August 1st. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a £120 ($145.00) price objective on shares of AstraZeneca in a report on Monday, August 1st. Finally, Citigroup reissued a "buy" rating on shares of AstraZeneca in a research note on Tuesday, July 12th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of £106.96 ($129.24).